Table 1.

Baseline characteristics of C&A patients with hepatocellular carcinoma (HCC)

Variable
Age	17 (8–20)
Sex
Female	13 (20%)
Male	52 (80%)
HBV infection
No	12 (18.5%)
Yes	53 (81.5%)
ALT (U/L)	64.5 ± 81.6
AST (U/L)	94.3 ± 130.6
ALB (g/L)	42.9 ± 5.2
TBIL (μmol/L)	22.4 ± 25.4
Tumor diameter (cm)	10.2 ± 4.1
AFP (ng/mL)
≤25	6 (9.2%)
>25	59 (90.8%)
Tumor number
Solitary	25 (38.5%)
Multiple	40 (61.5%)
Distant metastasis
No	54 (83.1%)
Yes	11 (16.9%)
Portal vein tumor thrombus
No	45 (69.2%)
Yes	20 (30.8%)
TNM stage
I	9 (13.8%)
II	8 (12.3%)
IIIA	22 (33.8%)
IIIB	14 (21.5%)
IVA	1 (1.5%)
IVB	11 (16.9%)
Initial treatment
ST	16 (24.6%)
TACE	23 (35.4%)
Resection	26 (40%)

HBV hepatitis B virus, ALT alanine aminotransferase, AST aspartate transaminase, ALB albumin, TBIL total bilirubin, AFP alpha-fetoprotein, TNM tumor-node-metastasis, ST supportive treatment, TACE transcatheter arterial chemoembolization